Abstract: Cyclosporine compositions for topical ophthalmic use for treatment of immune disorders, to enhance or restore tear production, and to enhance or effect normal healing of the surface of the eye, containing cyclosporine dissolved in corn oil. The composition may further include antioxidants, lubricants, antibiotics, antifungals, antivirals, pilocarpine, vasoconstrictors, surfactants, wetting agents, anti-inflammatory agents (i.e. corticosteroids), preservatives, mucolytic agents (i.e. bromhexine, acetylcysteine), as well as other compounds.The preferred composition is 2% cyclosporine, 1 mole % alpha tocopherol and 0.005% methyl paraben in corn oil.

Abstract: Aminoglycosides, analogs and derivatives thereof, in the form of phosphate salts are described as well as the process for making and utilizing same. Aminoglycoside phosphate liposomes and nonguanadino aminoglycoside phosphate liposomes, their preparation and use, are particularly described.

Abstract: An ophthalmologic gel is disclosed having a viscosity in the range of about 10,000 to about 50,000 mPa.s and comprising (1) about 0.05 to about 3% by weight of one or more polyacrylates and (2) about 0.1 to about 10% by weight one or more water-soluble, physiologically compatible polymers selected from the group consisting of polyvinyl alcohol, dextran, and mixtures thereof.

Abstract: A disinfectant or preservative composition particularly adapted for use in ophthalmic preparations such as contact lens disinfecting, cleaning, cushioning, wetting, soaking and reconditioning solutions and additionally in topical medications and tear substitutes, which uses a hydrophilic polymeric antimicrobial agent, namely poly[oxyethylene(dimethylimino) (ethylene dimethylimino)ethylene dichloride] with additional agents including EDTA and alkali salts thereof and a boric acid/borate buffer system.

Abstract: A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir comprising the effective agent; a first coating layer, which is essentially impermeable to the passage of the effective agent; and a second coating layer, which is permeable to the passage of the effective agent. The first coating layer covers at least a portion of the inner core; however, at least a small portion of the inner core is not coated with the first coating layer. The second coating layer essentially completely covers the first coating layer and the uncoated portion of the inner core.

Abstract: Aqueous solutions for treating inflammations of the eye, comprising: from about 0.03-3 weight percent of piroxicam; an effective amount of a buffer; from about 0 to about 1 weight percent of a wetting agent; from about 0 to about 5 weight percent of a pH adjusting agent; from about 0 to about 5 weight percent of a tonicity agent; an effective amount of a preservative; from about 0 to about 3 weight percent of a demulcent polymer; from about 0 to about 40 weight percent of a complexing agent; and from about 0 to about 0.1 weight percent of a stabilizer; and having a pH between about 7 and about 10.

Abstract: Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions are disclosed. The compositions contain a combination of a glucocorticoid and tetrahydrocortisol. The tetrahydrocortisol serves to substantially prevent any significant increases in intraocular pressure which might otherwise be experienced by the patient as a side effect of the glucocorticoid component of the compositions. The therapeutic interaction of the two components therefore allows the potent antiinflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure. A method of preventing increases in intraocular pressure attributable to systemic or topical corticosteroid therapy is also disclosed. That method involves the administration of a pharmaceutical composition containing tetrahydrocortisol to a patient receiving such therapy.

Abstract: Topical ophthalmic medicament delivery system combining an aqueous ophthalmic gel suspension at a pH equal to or greater than 7.5 and an osmotic pressure of from 10 to about 400 mOsM containing a pharmaceutically effective amount of one or more ophthalmic medicaments of from about 0.05% to about 10% by weight, based on the total weight of the suspension, of a carboxyl-containing polymer prepared by polymerizing one or more carboxyl-containing monoethylenically unsaturated monomers and less then about 5% by weight of a cross-linking agent. The systems have a viscosity of from about 1,000 to about 30,000 centiposes prior to administration to the eye and remain a gel in the eye for a prolonged period of time allowing for the sustained release of one or medicaments such as amine containing antibiotics alone or in combination with cortiscosteroids.

Abstract: Methods for the treatment of Microsporidia keratoconjunctivitis and Acanthamoeba keratitis are disclosed that include the topical administration of an effective amount of fumagillin or a derivative or pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier or diluent.

Abstract: Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical body cavity or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of a mammal; as protective corneal shields; or as ablatable corneal masks useful in laser reprofiling of the cornea. The compositions without the addition of a drug or diagnostic agent are useful as medical devices, for instance, in separating surgically or otherwise injured tissue as a means of preventing adhesions.

Abstract: A disinfectant or preservative composition particularly adapted for use in ophthalmic preparations such as contact lens disinfecting, cleaning, cushioning, wetting, soaking and reconditioning solutions and additionally in topical medications and tear substitutes, which uses a hydrophilic polymeric antimicrobial agent, namely poly[oxyethylene(dimethylimino) (ethylene dimethylimino)ethylene dichloride] with additional agents including EDTA and alkali salts thereof and a boric acidborate buffer system.

Abstract: Sustained release pharmaceutical compound delivery compositions and methods for their production are disclosed wherein ion exchange resin particles are loaded with releasably bound pharmaceutical compounds prior to incorporation in an erodible polymeric matrix to form microparticulates. The microparticulates are suspended in a fluid medium where the encapsulating polymeric matrix shields the drug loaded ion exchange resin from solvent interaction. Administration to a target tissue site initiations erosion of the polymer matrix and release of the loaded pharmaceutical compound.

Abstract: A method for treating a body condition comprising introducing an aqueous solution of a water soluble polyether polyurethane into said body condition.

Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.

Abstract: The object of the invention is an ophthalmic composition containing between 0.1 to 10% by weight of paracetamol in an ophthalmic excipient.

Abstract: Disclosed are water based, viscoelastic compositions comprising a mixture of high molecular weights hyaluronic acid salts and water soluble poly(ethylene oxides). Also disclosed are cosmetic formulations including said compositions.

Abstract: Methods and compositions for preventing or treating ophthalmic diseases or disorders wherein an ophthalmically effective amount of the C.sub.20 through C.sub.26 aminosteroids of formula XI and their pharmaceutical, acceptable salts, hydrates or solvates is administered in an inert vehicle to arrest oxidation processes damaging to the eye.

Abstract: Methods and compositions for preventing or treating ophthalmic diseases or disorders wherein an ophthalmically effective amount of the C.sub.20 through C.sub.26 aminosteroids of formula XI and their pharmaceutical, acceptable salts, hydrates or solvates is administered in an inert vehicle to arrest oxidation processes damaging to the eye.

Abstract: Reversibly gelling aqueous compositions are disclosed which undergo significant changes in viscosity in response to substantially simultaneous changes in both temperature and pH. The compositions are formed of relatively low concentrations of a stable combination of at least one pH-sensitive reversibly gelling polymer and at least one temperature-sensitive reversibly gelling polymer. The compositions can be formulated to exhibit a sol-gel transition over a wide range of conditions and viscosities and may be modified to incorporate a pharmaceutical compound for utilization as droppable or injectable drug delivery systems which will gel following administration to a physiological system for the sustained delivery of such pharmaceutical compounds.

Abstract: A method is provided for treating a hypersensitivity disease comprising administering to a human afflicted with such a disease an amount of an anionic polymer effective to counteract the symptoms of a disease selected from the group consisting of bronchial asthma, eosinophil-associated nasal inflammation and vernal conjunctivitis, by counteractBACKGROUND OF THE INVENTIONThis invention was made with the assistance of NIH under grant number AI-09728. The U.S. Government has certain rights in the invention.

Abstract: A method of treatment of inflammatory diseases which comprises administering, to a subject in need of such treatment, an anti-inflammatory effective amount of a polyoxyethylenesorbitan mono-higher-fatty acid ester.

Abstract: A method for treating cutaneous and corneal wounds as well as certain microbial-related diseases comprises topically applying a defensin peptide to the affected tissue. The compositions comprise a natural, synthetic, or analog defensin molecule having both a mitogenic activity capable of stimulating cell growth and an antimicrobial activity capable of inhibiting the growth of a wide variety of pathogens. In addition to therapeutic use, the defensins are useful as mitogens in cell and tissue culture media.

Abstract: A piracetam-containing preparation is applied to prevent and/or treat recurrent herpetic lesions. When used prophylactically, the piracetam-containing preparation is applied during the prodromal phase of a herpes recurrence at the site of previous eruptions. When used for treatment purposes, the piracetam-containing preparation is initially applied within six to twelve hours of the appearance of the herpetic lesions and application is continued at set intervals until the lesions disappear.

Abstract: Methods and compositions for preventing or treating ophthalmic diseases or disorders wherein an ophthalmically effective amount of the C.sub.20 through C.sub.26 aminosteroids of formula XI and their pharmaceutical, acceptable salts, hydrates or solvates is administered in an inert vehicle to arrest oxidation processes damaging to the eye.

Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.

Abstract: An ophthalmic formulation comprising a salt of sepazonium or a similar imidazolium compound as a preservative is provided.

Abstract: Two solutions capable of gel formation are simultaneously or successively applied to the mucous membrane of the eye for the purpose of treating diseases of the eye.

Abstract: Lightly crosslinked polymers, preferably ones prepared by suspension or emulsion polymerizing at least about 90% by weight of a carboxyl-containing monoethylenically unsaturated monomer such as acrylic acid with from about 0.1% to about 5% by weight of a polyfunctional, and preferably difunctional, crosslinking agent such as divinyl glycol (3,4-dihydroxy-1,5-hexadiene), having a particle size of not more than about 50 .mu.m in equivalent spherical diameter, when formulated with an ophthalmic medicament, e.g., fluorometholone, into suspensions in aqueous medium in which the amount of polymer ranges from about 0.1% to about 6.5% by weight, based on the total weight of the aqueous suspension, the pH is from about 3.0 to about 6.

Abstract: A topical, aqueous ophthalmic gel suspension for dry eye is administrable to the eye in drop form, remains as a gel in the eye for a prolonged time, and releases water and one or more ophthalmic demulcents or vasoconstrictors. It comprises water and from 0.1% to 6.5% by weight of lightly cross-linked carboxyl-containing polymer having a particle size of not more than about 50 .mu.m in equivalent spherical diameter. The suspension is at a pH of from 6.6 to 8.0, has an osmolality of from 50 to 400 mOsM, and a viscosity of from about 500 to about 4,000 centipoise (0.5 to 4 Pa.s).

Abstract: Encapsulated agents are employed for introduction into the suprachoroid of an eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.

Abstract: Vitronectin produces very high therapeutic effects upon injuries of the corneal epithelium. When applied to lesions of the corneal epithelium in the form of eye drops, Vitronectin induces rapid cure of the lesions with regeneration of normal cells. Moreover Vitronectin can be sterilized by autoclaving.

Abstract: Glycosaminoglycan polysulfates (GAGPS) have been found to be useful in ophthalmic medications in the prevention and treatment of eye injuries. Particularly useful are GAGPS having a molecular weight in the range of 5,000-20,000 daltons. GAGPS-containing ophthalmic medications are usefully combined with an antibiotic in the treatment of ocular fungal or bacterial infections or with an antibiotic in the treatment of fungal or bacteria infections or with an anti-glaucoma agent, such as pilocarpine or epinephrine, in the treatment of glaucoma. Also, of particular usefulness are GAGPS solutions or dispersions used to enhance healing after corneal abrasion or surgical insult.

Abstract: Stable, clear, antimicrobially effective, ophthalmic formulations include an ophthalmologically effective amount of a drug, especially a --COOH group-containing drug or a NSAID, and a preservative system formed of a quaternary ammonium preservative and a nonionic surfactant, all in an aqueous vehicle. These formulations are useful for treating diseases that are either caused by, associated with or accompanied by inflammatory processes, including, among others, glaucoma, cystoid macular edema, uveitis, diabetic retinopathy and conjunctivitis, or any trauma caused by eye surgery or eye injury.

Abstract: The invention relates to combination preparations containing chloramphenicol, gentamicin, nystatin and optionally a cortisone as active ingredients for the topical treatment of inflammatory skin disorders. The preparations are present preferably in the form of an ointment and have proved to be surprisingly effective particularly in the case of the treatment of skin disorders which are difficult to heal such as chronic eczema, inflammations in the anal and genital region, and of ulcus cruris and similar disorders.

Abstract: A benzonaphthalene compound has the formula ##STR1## wherein R.sub.1 represents ##STR2## or (ii) --CH.sub.2 OH; R.sub.6 represents ##STR3## or OR.sub.7 wherein R.sub.7 represents hydrogen, alkyl having 1-20 carbon atoms, monohydroxyalkyl or polyhydroxyalkyl, r' or r" represent hydrogen, lower alkyl, mono or polyhydroxyalkyl, aryl or a residue of an amino acid or a sugar, or together form a heterocycle; R.sub.2 represents hydrogen, alkyl having 1-15 carbon atoms, alkoxy having 1-4 carbon atoms or a cycloaliphatic radial; R.sub.3 represents hydrogen, hydroxy, alkyl having 1-4 carbon atoms, alkoxy having 1-10 carbon atoms, a cycloaliphatic radical, a thiocycloaliphatic radical or --O--Si(CH.sub.3).sub.2 --R.sub.8 wherein R.sub.8 represents lower alkyl; and R.sub.4 and R.sub.5 represent hydrogen, lower alkyl, hydroxy or lower acyloxy.This compound is useful in the topical and systemic treatment of dermatologic diseases and in the treatment of the degeneration of conjunctive tissues.

Abstract: Balanced pH, thermo-irreversible gels are ideal vehicles for drug delivery to the eye of a mammal.

Abstract: The invention relates to a method of treating painful, inflammatory or allergic disorders comprising treatment with an effective amount of a composition comprising cis-8-methyl-N-vanillyl-6-nonenamide. The invention also relates to compositions for use in the inventive method.

Abstract: Improved healing of wounds, particularly wounds of the eye, such as keratorefractive surgical incisions, is obtained by coating the wound surfaces with a solution containing a protein crosslinking compound such as dimethyl pimelimidate dihydrochloride, followed by treatment with a composition containing an extracellular matrix material such as fibronectin, a biologically active fragment or an analog thereof.

Abstract: A topical drug application for the alleviation of keratoconjunctivitis sicca (dry eye syndrome) is comprised of a solution of sex steroids or their derivatives suspended or dissolved in a vehicle, and the method of preparation and application of the same. In the preferred embodiments, the sex steroid consists essentially of conjugated estrogen in a lipid vehicle or a derivative of estrogen known as 17 beta-Estradiol 3-phosphate disodium dissolved in an aqueous vehicle having a pH of between 6 and 8.

Abstract: This invention relates to low irritative ophthalmics containing the compound of the formula or salts thereof which are useful for treatment of anti-allergic eye diseases such as allergic conjunctivitis ##STR1##

Abstract: Novel compositions of matter are provided herein which are the reaction product of polyvinylpyrrolidone and hypochlorites. These compositions are useful as antimicrobial agents.

Abstract: Lipophilic quaternary ammonium salicylate, characterized in that it corresponds to the formula: ##STR1## in which: (i) R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be identical or different, denote an alkyl or alkylcycloalkyl radical, optionally substituted or interrupted;(ii) R.sub.3 and/or R.sub.4 denote(s) a group:R.sub.8 [OC.sub.2 H.sub.3 R.sub.7 ].sub.n [OCH.sub.2 CHOH--CH.sub.2 ].sub.pin which 0.ltoreq.n.ltoreq.4 and p denotes 0 or 1; R.sub.8 denotes H or an alkyl, alkenyl, alkylcycloalkyl or alkylaryl radical;(iii) R.sub.4 denotes an alkylphenyl radical;(iv), (v) R.sub.1 and R.sub.2 can form a saturated or unsaturated aromatic or non-aromatic heterocycle;(vi) R.sub.1, R.sub.2 and R.sub.3 form polycyclic derivatives with the nitrogen atoms; R.sub.5 denotes a group corresponding to the formula: ##STR2## in which n is an integer varying between 0 and 10.

Abstract: Pharmaceutical compositions comprising tetrahydrocortisol and method of using same in the control of intraocular pressure are disclosed.

Abstract: Disclosed are ophthalmic pharmaceutical compositions comprising S(+)-flurbiprofen substantially free of R(+)-flurbiprofen and methods of topical administration to the eye when indicated for treatment of inflammation.

Abstract: The present invention concerns a pharmaceutical and/or cosmetic composition designed to be applied on the skin or the mucosae, characterized in that it contains Rhamsan gum.

Abstract: Cyclosporins are useful immunosuppressive, anti-fungal and antiphlogistic agents which are relatively insoluble in water and aqueous fluids (including body fluids). They may be rendered more soluble or dispersible in aqueous media by first dissolving them in at least one mono- or di- glyceride of a C.sub.6 -C.sub.10 fatty acid, and the resulting solution can then easily be emulsified in water or an aqueous fluid.

Abstract: Storage stable aqueous ophthalmic, substantially isotonic solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl) aminophenylacetic acid, and having a pH of about 7.0 to about 7.8, comprising per ml solution:(a) about 0.1 to about 5.0 mg of a pharmaceutically acceptable salt of ortho-(2,6-dichlorophenyl)aminophenylacetic acid;(b) about 0.1 to about 10 mg of a pharmaceutically acceptable salt of ethylenediamine tetraacetic acid;(c) about 0.5 to about 200 mg of a pharmaceutically acceptable solubilizer;(d) about 0.01 to about 5.0 mg of a pharmaceutically acceptable bacteriostat; and(e) the remainder water,and the use of such solutions, by topical administration to the eye of a warm blood mammal, for the control or treatment of ocular inflammation.

Abstract: A method and composition for treating blepharitis or blepharoconjunctivitis comprises topical administration of a nitroimidazole compound, e.g. metronidazole in a suitable carrier directly to affected ocular tissues. The carrier can be an artificial tear solution or an ointment or water soluble gel base.

Abstract: A benzonaphthalene compound has the formula ##STR1## wherein R.sub.1 represents ##STR2## or (ii) --CH.sub.2 OH; R.sub.6 represents ##STR3## or OR.sub.7 wherein R.sub.7 represents hydrogen, alkyl having 1-20 carbon atoms, monohydroxyalkyl or polyhydroxyalkyl, r' or r" represent hydrogen, lower alkyl, mono or polyhydroxyalkyl, aryl or a residue of an amino acid or a sugar, or together form a heterocycle; R.sub.2 represents hydrogen, alkyl having 1-15 carbon atoms, alkoxy having 1-4 carbon atoms or a cycloaliphatic radial; R.sub.3 represents hydrogen, hydroxy, alkyl having 1-4 carbon atoms, alkoxy having 1-10 carbon atoms, a cycloaliphatic radical, a thiocycloaliphatic radical or --O--Si(CH.sub.3).sub.2 --R.sub.8 wherein R.sub.8 represents lower alkyl; and R.sub.4 and R.sub.5 represent hydrogen, lower alkyl, hydroxy or lower acyloxy.This compound is useful in the topical and systemic treatment of dermatologic diseases and in the treatment of the degeneration of conjunctive tissues.

Abstract: A topical drug application for the alleviation of kerato-conjunctivitis sicca (dry eye syndrome) is comprised of a solution of sex steroids or their derivatives suspended or dissolved in a vehicle, and the method of preparation and application of the same. In the preferred embodiments, the sex steroid consists essentially of conjugated estrogen in a lipid vehicle or a derivative of estrogen known as 17 beta-Estradiol 3-phosphate disodium dissolved in an aqueous vehicle having a pH of between 6 and 8.